Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 8/20 | 0.52 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.49 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.48 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.48 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.48 |
| ▸ | FAAH | O00519 | 1/20 | 0.46 |
| ▸ | MGLL | Q99685 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | CYP2J2 | P51589 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6623432 | 0.85 | EPHX2 (0.52) | EPHX2PTGS2AKR1C2AKR1C1AKR1C3 | |
| SCHEMBL7985890 | 0.83 | AKR1C3 (0.50) | PTGS2AKR1C3 | |
| SCHEMBL3798133 | 0.82 | EPHX2 (0.50) | EPHX2PTGS2AKR1C2AKR1C1AKR1C3 | |
| SCHEMBL7505910 | 0.82 | EPHX2 (0.54) | EPHX2PTGS2AKR1C2AKR1C1AKR1C3 | |
| SCHEMBL6184286 | 0.82 | EPHX2 (0.54) | EPHX2PTGS2AKR1C2AKR1C1AKR1C3 | |
| SCHEMBL7507298 | 0.82 | EPHX2 (0.54) | EPHX2PTGS2AKR1C2AKR1C1AKR1C3 | |
| SCHEMBL8562014 | 0.81 | EPHX2 (0.53) | EPHX2PTGS2AKR1C2AKR1C1AKR1C3 | |
| SCHEMBL7084244 | 0.81 | EPHX2 (0.53) | EPHX2PTGS2AKR1C2AKR1C1AKR1C3 | |
| SCHEMBL5781468 | 0.76 | EPHX2 (0.55) | EPHX2PTGS2AKR1C2AKR1C1AKR1C3 | |
| SCHEMBL6050635 | 0.76 | CES2 (0.64) | EPHX2PTGS2AKR1C2AKR1C1AKR1C3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1556364-A4 | ISOTHIAZOLE DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF, AND PHARMACEUTICAL COMPOSITION INCLUDING THE SAME | CJ CORP (KR) | 2008-04-16 | — | — | EP | disclosed |
| US-6967213-B2 | Isothiazole derivatives, process for the preparation thereof, and pharmaceutical composition including the same | CJ CORP. (KR) | 2005-11-22 | — | — | US | disclosed |
| EP-1556364-A1 | ISOTHIAZOLE DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF, AND PHARMACEUTICAL COMPOSITION INCLUDING THE SAME | CJ Corp. (KR) | 2005-07-27 | — | — | EP | disclosed |
| WO-2004035553-A1 | ISOTHIAZOLE DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF, AND PHARMACEUTICAL COMPOSITION INCLUDING THE SAME | CJ CORP. (KR) | 2004-04-29 | — | — | WO | disclosed |
| US-20040072884-A1 | Isothiazole derivatives, process for the preparation thereof, and pharmaceutical composition including the same | CJ CORP. (KR) | 2004-04-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040072884-A1 | Isothiazole derivatives, process for the preparation thereof, and pharmaceutical composition including the same | CYP3A5, CYP2C9, CYP2C19 | EPHX2 2398/4885PTGS2 152/4885AKR1C2 1275/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.